Clinical trials: Breast Neoplasms, Triple-Negative
Breast Cancer
Bevacizumab, Docetaxel, and Carboplatin in Treating Women With Stage II or Stage III Breast Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01208480
- Testing
- Avastin, docetaxel, carboplatin
- Where
- South Korea
- Volunteers
- 45 people
- Sponsor
- Severance Hospital
Carcinoma Breast Stage IV
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT02183805
- Testing
- Abraxane,Cyclophosphamide,Carboplatin
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
TNBC - Triple-Negative Breast Cancer, Breast Cancer
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
Open label, single-arm, prospective therapeutic trial. Pembrolizumab (MK-3475), 200 mg IV Q3W starting at C1D1/Week 1 for up to 2 years, until disease progression, or treatment intolerance.
- Trial name
- NCT07015853
- Testing
- Pembrolizumab, Radiotherapy, Axatilimab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Stephen Shiao
Metastatic Breast Cancer
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
This is a single center, non-blinded, multi-cohort, non-comparative phase II trial to study the safety and efficacy of tiragolumab with atezolizumab and/or ipilimumab in advanced triple-negative breast cancer.
- Trial name
- TONIC-3 (NCT06342037)
- Testing
- Tiragolumab, Atezolizumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- The Netherlands Cancer Institute
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
- Trial name
- NCT06700070
- Testing
- PBA-0111
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Pure Biologics S.A.
Breast Cancer, Triple Negative Breast Cancer
Exercise Intervention in Women Diagnosed With Triple-negative Breast Cancer Receiving Oncologic Treatment
In this randomized, controlled, prospective, two-arm intervention study, the investigators plan to investigate the effects of high-intensity interval training in women diagnosed with triple-negative breast cancer.
- Trial name
- NCT06497322
- Testing
- Exercise intervention - High intensity interval training on a cycle-ergometer
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University Hospital of Cologne
Triple Negative Breast Cancer
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer
Triple-negative breast cancer is a subtype of breast cancer that is clinically negative for expression of estrogen and progesterone receptors (ER/PR) and HER2 protein.
- Trial name
- TNBC (NCT03168880)
- Testing
- Paclitaxel + Carboplatin, Paclitaxel only
- Where
- India
- Volunteers
- 720 people
- Sponsor
- Tata Memorial Hospital
Triple Negative Breast Cancer, Immune Checkpoint Inhibitor
LAG3 Expression in Triple Negative Breast Cancer
This study is the experimental study for relationship between LAG-3 expression / immue checkpoint protein expression and neoadjuvant chemotherapy plus immune checkpoint inhibitor in triple negative breast cancer.
- Trial name
- NCT06259162
- Testing
- LAG-3 expression / immune checkpoint protein expression
- Where
- South Korea
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center
Triple Negative Breast Cancer
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
This study evaluates efficacy of LY3023414 and prexasertib in patients with metastatic triple negative breast cancer.
- Trial name
- NCT04032080
- Testing
- Drug 1: LY3023414; Drug 2: Prexasertib
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Baylor Research Institute
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
This phase I trial tests the safety, side effects, and best dose of ZEN003694 in combination with binimetinib in treating patients with solid tumors that carry RAS alterations and that have spread to other places in the body…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma
- Trial name
- NCT05111561
- Testing
- BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure
- Where
- 4 sites in United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Triple Negative Breast Cancer Patients
Study of Neoadjuvant Treatment of Locally Advanced Breast Cancer With CAP Regimen
This is a single arm, single center, non-randomized, phase II trial of stage IIB/III TNBC. Patients received neoadjuvant chemotherapy with cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500…
- Trial name
- CAPneo (NCT03304756)
- Testing
- CAP
- Volunteers
- 41 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Breast Neoplasms
CTC Changes and Efficacy of Neoadjuvant Chemotherapy for Triple-negative Breast Cancer
Chemotherapy before operation for malignant tumors can reduce the size of tumors to a certain extent, even eliminate micrometastases.
- Trial name
- NCT04059003
- Testing
- Taxanes or/and anthracycline-based therapy
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Shengjing Hospital
Metastatic Uveal Melanoma, Triple Negative Breast Cancer
Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR)
Resistance to treatment is one of the major themes in cancer research. Despite this, the definition and clinical implications of resistance to treatment remain under-explored, and patient-physician communication in this context…
- Conditions
- Metastatic Uveal Melanoma, Triple Negative Breast Cancer, Luminal B Breast Cancer, Pediatric Cancer
- Trial name
- NCT04118062
- Testing
- Questionnaires, Semi-structured individual interviews, Focus Group
- Where
- France
- Volunteers
- 128 people
- Sponsor
- Institut Curie
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases
This phase I/II trial studies the best dose and effect of pimasertib in combination with bintrafusp alfa in treating patients with cancer that has spread to the brain (brain metastases).
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm, Hormone Receptor Positive Breast Adenocarcinoma
- Trial name
- NCT04789668
- Testing
- Bintrafusp Alfa, Pimasertib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- M.D. Anderson Cancer Center
TNBC, Triple Negative Breast Cancer
Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer
This study is a multicenter, single-arm, investigator-initiated Phase II clinical trial. Eligible patients with treatment-naive early or locally advanced triple-negative breast cancer (TNBC), clinically staged as Stage II-III…
- Trial name
- NCT06977542
- Testing
- Ivonescimab
- Volunteers
- 53 people
- Sponsor
- Fudan University
Breast Cancer
A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer
The purpose of this clinical trial was to determine whether combining iniparib (BSI-201) with standard chemotherapy in estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor…
- Trial name
- NCT00540358
- Testing
- gemcitabine/carboplatin, iniparib
- Where
- 18 sites in United States
- Volunteers
- 123 people
- Sponsor
- Sanofi
Metastatic Breast Cancer
Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast Cancer
The objective of this study is to evaluate the safety and tolerance of Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients in Metastatic Triple Negative Breast Cancer
- Trial name
- NCT03151447
- Testing
- stereotactic body radiation therapy
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Fudan University
Solid Tumor, Adult, Bladder Cancer
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
This is an open-label pilot study of a new PET/CT imaging agent MNPR-101-DFO*-89Zr in patients with solid tumor cancers. These cancers may include bladder/urothelial, triple-negative breast, lung, colorectal, gastric, ovarian…
- Conditions
- Solid Tumor, Adult, Bladder Cancer, Urothelial Carcinoma, Triple-negative Breast Cancer
- Trial name
- NCT06337084
- Testing
- MNPR-101-DFO*-89Zr, PET/CT Diagnostic Imaging
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Monopar Therapeutics
Primary Breast Cancer
Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)
Cabazitaxel is a new taxoid which promotes the tubulin assembly in vitro and stabilizes microtubules against cold-induced depolymerization as efficiently as docetaxel and was selected for development based on a better…
- Trial name
- NCT01779479
- Testing
- Cabacitaxel, Paclitaxel
- Where
- Germany
- Volunteers
- 333 people
- Sponsor
- GBG Forschungs GmbH
Breast Cancer Recurrent
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
This is a prospective phase 2 study to use Functional Precision Oncology (FPO) to predict, prevent and treat early metastatic recurrence in subjects with HR-low/Her2 negative or triple negative breast cancer.
- Trial name
- TOWARDS-II (NCT05464082)
- Testing
- Functional Precision Oncology
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- University of Utah
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.